Lipoprotein disorders are significant due to their role in atherogenesis and the consequent risk of atherosclerotic cardiovascular disease (ASCVD). Lowering cholesterol demonstrably reduces cardiovascular mortality and events in both secondary and primary prevention contexts. This activity provides a detailed overview of Hypercholesterolemia Diagnosis, etiology, and management, emphasizing the crucial role of an interprofessional healthcare team.
Etiology of Hypercholesterolemia
Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is diagnosed based on LDL-cholesterol levels. Elevated LDL-C is defined as:
- LDL-C greater than 190 mg/dL
- LDL-C greater than 160 mg/dL with one major risk factor
- LDL-C greater than 130 mg/dL with two cardiovascular risk factors
Major cardiovascular risk factors include:
- Age: Male ≥ 45 years, Female ≥ 55 years
- Family history of premature ASCVD (male < 55 years, female < 65 years)
- Hypertension
- Diabetes mellitus
- Smoking
- Low HDL-cholesterol (male < 40 mg/dL, female < 55 mg/dL)
Hypercholesterolemia can arise from both genetic and acquired factors. Familial hypercholesterolemia (FH) is a primary genetic disorder caused by mutations in the LDL-receptor gene. This leads to significantly elevated LDL-C levels, often exceeding 190 mg/dL in heterozygotes and 450 mg/dL in homozygotes. Mutations in the LDL receptor gene are responsible for the majority of FH cases, impairing the liver’s ability to clear LDL from the bloodstream.
Other genetic causes of FH include defects in apolipoprotein B and gain-of-function mutations in the PCSK9 gene. These genetic forms of hypercholesterolemia are typically inherited in an autosomal dominant pattern. Autosomal recessive hypercholesterolemia, due to mutations in the LDL receptor adaptor protein, is a rarer genetic cause.
Polygenic hypercholesterolemia, resulting from a combination of genetic predispositions and lifestyle factors like sedentary behavior and diets high in saturated and trans-fatty acids, is the most common form. Secondary hypercholesterolemia can be triggered by conditions such as hypothyroidism, nephrotic syndrome, cholestasis, pregnancy, and certain medications (cyclosporine, thiazide diuretics). These secondary causes should be considered and ruled out during hypercholesterolemia diagnosis.
Image alt text: Diagram illustrating the interplay of genetic and acquired factors contributing to hypercholesterolemia, including familial hypercholesterolemia and lifestyle influences.
Epidemiology of Hypercholesterolemia
Hypercholesterolemia is a widespread health concern. The Centers for Disease Control and Prevention (CDC) reports that 31.7% of adults in the United States, or 73.5 million individuals, have high LDL-C levels. This condition doubles the risk of heart disease compared to those with normal cholesterol levels. Alarmingly, only 48.1% of those with high LDL-C are receiving treatment to manage it.
Familial hypercholesterolemia, while a specific genetic subtype, also has a notable prevalence. Homozygous FH is estimated to occur in 1 in 300,000 individuals, while heterozygous FH is significantly more common, affecting approximately 1 in 250 people. In certain populations, such as French Canadians, Lebanese, and Afrikaners, the prevalence of heterozygous FH can be as high as 1 in 100.
Within the US, Hispanic males exhibit the highest levels of LDL cholesterol, followed by African Americans and White males. Overall, elevated LDL-C is more prevalent in females than males. These epidemiological data underscore the importance of effective hypercholesterolemia diagnosis and management across diverse populations.
Pathophysiology of Hypercholesterolemia
The pathophysiology of hypercholesterolemia, particularly in familial hypercholesterolemia, centers on disruptions in LDL receptor function. The LDL receptor, primarily located in the liver, is crucial for removing LDL cholesterol from the bloodstream. In FH, genetic defects lead to either a deficiency or dysfunction of these receptors. Without effective LDL receptors, the liver cannot efficiently process and remove LDL cholesterol, leading to its accumulation in the blood. Normally, the liver processes approximately two-thirds of circulating LDL.
The consequence of impaired LDL receptor function is a buildup of LDL cholesterol in the circulation. This elevated LDL-C contributes directly to atherogenesis, the process of plaque formation in arteries, increasing the risk of cardiovascular diseases. Hundreds of different mutations in the LDL receptor gene have been identified, each potentially contributing to varying degrees of hypercholesterolemia. Understanding this pathophysiology is fundamental to comprehending the need for accurate hypercholesterolemia diagnosis and targeted treatment strategies.
History and Physical Examination in Hypercholesterolemia Diagnosis
A thorough patient history and physical examination are essential first steps in hypercholesterolemia diagnosis. The history should include a detailed family history, specifically inquiring about premature atherosclerotic cardiovascular disease. Constructing a family tree can be valuable in identifying potential familial hypercholesterolemia. It’s also crucial to gather information on modifiable risk factors such as smoking, diabetes, dietary habits (total calories, saturated and trans fats), physical activity levels, and current medications. Inquire about any symptoms suggestive of cardiovascular disease, including angina pectoris, intermittent claudication, or transient ischemic attacks. Consider potential secondary causes by asking about symptoms of hypothyroidism, nephrotic syndrome, or cholestasis.
The physical examination should include assessment for signs of secondary causes like hypothyroidism (bradycardia, dry skin, delayed reflexes) and nephrotic syndrome (edema, ascites), cholestasis (jaundice, hepatomegaly). Palpate peripheral pulses and auscultate for carotid and femoral bruits, which can indicate underlying atherosclerosis. Carefully examine for physical manifestations of hypercholesterolemia, such as tendon xanthomas (Achilles tendon, extensor tendons of the hand), xanthelasma (yellowish plaques around the eyelids), and arcus senilis (a gray or white arc around the cornea, especially in individuals under 50 years old). In patients suspected of familial hypercholesterolemia, a cardiac examination to assess for supravalvular aortic stenosis due to atheroma deposition is warranted. These historical and physical findings provide valuable clues in the diagnostic process of hypercholesterolemia.
Image alt text: Illustration depicting visible physical signs associated with hypercholesterolemia, including tendon xanthomas on the hand and xanthelasma around the eye.
Evaluation and Hypercholesterolemia Diagnosis
The cornerstone of hypercholesterolemia diagnosis is a plasma lipid profile. It is recommended that all adults over 40 years of age undergo lipid profile testing, ideally after a 10 to 12-hour overnight fast. The lipid profile measures total cholesterol, triglycerides, and HDL-cholesterol. LDL-cholesterol is typically calculated using the Friedewald Equation:
LDL-C = Total Cholesterol – VLDL(TG/5) – HDL-C
The Friedewald formula is accurate when performed on fasting plasma samples and when triglyceride levels are below 200 mg/dL. It is not reliable if triglyceride levels exceed 400 mg/dL. Direct LDL-C measurement methods are also available.
To exclude secondary causes of hypercholesterolemia, additional laboratory tests may be necessary. These include:
- TSH (thyroid-stimulating hormone) to rule out hypothyroidism
- Glucose testing to screen for diabetes
- Urinalysis and serum albumin to assess for nephrotic syndrome
- Bilirubin and alkaline phosphatase to evaluate for cholestasis
If an abnormal lipid profile indicating high cholesterol is detected, it is recommended to repeat the test within two weeks to confirm the diagnosis before initiating long-term therapy.
Screening Recommendations for Hypercholesterolemia Diagnosis:
Routine lipid profile screening is recommended for:
- Men older than 35 years
- Women older than 45 years
- Individuals with diabetes
- Tobacco users
- Individuals with a family history of cardiac disease
- Individuals with a personal history of heart disease or peripheral vascular disease
- Obese individuals (BMI > 30)
- Individuals with hypertension
These screening guidelines help identify individuals who would benefit from hypercholesterolemia diagnosis and subsequent management to reduce their cardiovascular risk.
Treatment and Management of Hypercholesterolemia
The foundation of hypercholesterolemia treatment is lifestyle modification. This includes adopting a healthy lifestyle with optimal weight management, smoking cessation, regular exercise (at least 150 minutes per week), and a diet low in saturated and trans-fatty acids, while rich in fiber, fruits, vegetables, and fatty fish. Plant stanols (2 g/day) can also aid in lowering LDL-C levels.
Pharmacological intervention is often necessary. Statins are the primary drug class for lowering LDL-C, capable of reducing LDL-C by 22% to 50%. Statins have demonstrated efficacy in reducing cardiovascular events in both primary and secondary prevention settings. Potential side effects of statins include elevated liver transaminases, myalgia, myopathy, and new-onset diabetes. If transaminase levels exceed three times the upper limit of normal, statin dose reduction or switching to a lower dose of another statin is recommended. Myopathy is a serious concern, potentially leading to rhabdomyolysis and acute renal failure. Certain drugs, such as gemfibrozil, macrolide antibiotics, azole antifungals, protease inhibitors, cyclosporine, nefazodone, and other CYP3A4 inhibitors, can increase the risk of statin-induced myopathy.
For patients who do not achieve adequate LDL-C control with statins alone, additional medications may be necessary. Cholesterol absorption inhibitors (ezetimibe) and/or bile acid sequestrants are often used in combination with statins due to their safety profile. Niacin may be considered in combination therapy for further LDL-C reduction in primary prevention, but its benefit in patients with established ASCVD is less clear.
LDL apheresis, a physical procedure to selectively remove LDL particles from the blood, is an option for patients with heterozygous FH whose LDL-C remains significantly elevated (above 200 mg/dL with CVD or above 300 mg/dL without CVD) despite maximally tolerated drug therapy. PCSK9 inhibitors (monoclonal antibodies) represent a newer class of drugs that can lower LDL-C by up to 60% when added to statin therapy. They are approved for use in FH and in patients on statins who have not reached their LDL-C goals.
For heterozygous FH, HMG-CoA reductase inhibitors may normalize LDL levels. However, achieving optimal LDL levels may require combinations of reductase inhibitors, niacin, bile acid sequestrants, and ezetimibe. In homozygous FH or compound heterozygosity, treatment is more challenging. Partial control may be achieved with medications like antisense oligonucleotides targeting Apo B-100 synthesis, microsomal triglyceride transfer protein inhibitors, and ezetimibe. Statins and PCSK9 inhibitors can be helpful if residual LDL receptor activity is present. Liver transplantation can dramatically reduce LDL levels, highlighting the liver’s central role in LDL metabolism.
The target LDL-C level for the general population is less than 100 mg/dL. For patients with ASCVD, the goal is even lower, less than 70 mg/dL or a 50% reduction in LDL-C. For other high-risk individuals, an LDL-C goal of less than 100 mg/dL or a 30% to 50% reduction is recommended.
Differential Diagnosis of Hypercholesterolemia
When considering hypercholesterolemia diagnosis, it’s important to consider and differentiate it from other conditions that may present with similar risk profiles or contribute to cardiovascular risk. The differential diagnosis includes:
- Smoking: While not directly related to cholesterol levels, smoking is a major independent risk factor for cardiovascular disease and often coexists with hypercholesterolemia.
- Hypothyroidism: This endocrine disorder can cause secondary hyperlipidemia, including elevated LDL-cholesterol.
- Diabetes Mellitus: Diabetes is a significant risk factor for ASCVD and is frequently associated with dyslipidemia.
- Nephrotic Syndrome: This renal condition can lead to secondary hypercholesterolemia due to alterations in lipid metabolism.
- Alcoholism: Excessive alcohol consumption can contribute to hypertriglyceridemia and may indirectly affect LDL cholesterol levels.
Distinguishing hypercholesterolemia from these conditions is crucial for accurate diagnosis and appropriate management strategies.
Prognosis of Hypercholesterolemia
The primary risk associated with hypercholesterolemia is the development of adverse cardiac events. However, the prognosis for individuals with hypercholesterolemia has significantly improved since the introduction of statin medications. Cholesterol-lowering therapies, particularly statins, have been proven to effectively reduce mortality and cardiovascular events in both primary and secondary prevention. Today, managing hypercholesterolemia is a cornerstone of primary prevention for heart disease, leading to improved long-term outcomes for many patients.
Complications of Hypercholesterolemia
Untreated or poorly managed hypercholesterolemia can lead to serious complications, primarily related to atherosclerotic cardiovascular disease:
- Heart Disease: Coronary artery disease, angina, myocardial infarction (heart attack)
- Stroke: Ischemic stroke due to thromboembolism
- Peripheral Vascular Disease: Intermittent claudication, limb ischemia
Early hypercholesterolemia diagnosis and effective management are essential to prevent or delay the onset of these debilitating and life-threatening complications.
Postoperative and Rehabilitation Care for Hypercholesterolemia
While hypercholesterolemia management is primarily medical, postoperative and rehabilitation care can reinforce lifestyle modifications and improve overall outcomes, particularly for patients undergoing cardiovascular procedures.
Dietary Guidelines:
- Total fat intake should be less than 30% of total energy intake.
- Saturated fat intake should be less than 7% of total calories.
- Carbohydrates should constitute approximately 60% of total calories.
Exercise:
- Regular aerobic exercise, while it may not directly lower LDL-C significantly, improves insulin sensitivity, reduces triglyceride levels, and increases HDL-cholesterol. It also contributes to overall cardiovascular fitness and weight management.
Enhancing Healthcare Team Outcomes in Hypercholesterolemia Management
Effective management of hypercholesterolemia requires a collaborative interprofessional team approach. This team ideally includes physicians, pharmacists, nurses, dietitians, and physical therapists, all working in concert to optimize patient care and outcomes.
- Nurses play a vital role in patient education regarding lifestyle modifications, healthy eating habits, and the importance of physical activity.
- Pharmacists ensure medication adherence, provide antismoking support, and monitor for potential statin side effects, including muscle pain and liver function abnormalities. They also verify regular blood work monitoring is in place.
- Dietitians provide individualized dietary counseling, educating patients on heart-healthy food choices and strategies to reduce fat intake.
- Physical Therapists guide patients in developing safe and effective exercise programs to achieve and maintain a healthy body weight.
- Mental Health Nurses or counselors can provide support for patients struggling with lifestyle changes or low morale.
Effective communication and coordination among team members are essential to ensure patients receive comprehensive and standardized care for hypercholesterolemia. Referral to bariatric surgery may be considered for patients who fail to achieve cholesterol lowering goals through other measures.
Outcomes of Hypercholesterolemia Management
The widespread availability of statins and a greater focus on lifestyle management have significantly improved outcomes for individuals with hypercholesterolemia. Effective management reduces the risk of adverse cardiovascular events and improves overall health. Lifestyle modifications often lead to beneficial changes in body weight, blood pressure, and glucose control, further reducing cardiovascular risk. Smoking cessation is also a critical factor in improving outcomes. Numerous studies consistently demonstrate that appropriate hypercholesterolemia diagnosis and management result in significantly better health outcomes and reduced cardiovascular morbidity and mortality.
Review Questions
(Note: Review questions from the original article are omitted as per instructions)
References
(References are included as in the original article)
1.Radaelli G, Sausen G, Cesa CC, Portal VL, Pellanda LC. Secondary Dyslipidemia In Obese Children – Is There Evidence For Pharmacological Treatment? Arq Bras Cardiol. 2018 Sep;111(3):356-361. [PMC free article: PMC6173338] [PubMed: 30156604]
2.Zawacki AW, Dodge A, Woo KM, Ralphe JC, Peterson AL. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. J Clin Lipidol. 2018 Nov-Dec;12(6):1445-1451. [PubMed: 30150142]
3.Wiegman A. Lipid Screening, Action, and Follow-up in Children and Adolescents. Curr Cardiol Rep. 2018 Aug 09;20(9):80. [PMC free article: PMC6097065] [PubMed: 30090990]
4.Dainis AM, Ashley EA. Cardiovascular Precision Medicine in the Genomics Era. JACC Basic Transl Sci. 2018 Apr;3(2):313-326. [PMC free article: PMC6059349] [PubMed: 30062216]
5.Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ., Convened by the Familial Hypercholesterolemia Foundation. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 Aug 07;72(6):662-680. [PubMed: 30071997]
6.Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management. Front Pharmacol. 2018;9:707. [PMC free article: PMC6052892] [PubMed: 30050433]
7.Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018 Aug 16;379(7):633-644. [PubMed: 30110583]
8.Ferrières J. Familial hypercholesterolaemia: a look toward the East. Kardiol Pol. 2018;76(6):935-936. [PubMed: 29905363]
9.Danese MD, Sidelnikov E, Kutikova L. The prevalence, low-density lipoprotein cholesterol levels, and treatment of patients at very high risk of cardiovascular events in the United Kingdom: a cross-sectional study. Curr Med Res Opin. 2018 Aug;34(8):1441-1447. [PubMed: 29627994]
10.Winter MP, Wiesbauer F, Blessberger H, Pavo N, Sulzgruber P, Huber K, Wojta J, Distelmaier K, Lang IM, Goliasch G. Lipid profile and long-term outcome in premature myocardial infarction. Eur J Clin Invest. 2018 Oct;48(10):e13008. [PubMed: 30062727]
11.Zuo HJ, Deng LQ, Wang JW. [Current status and the consistency analysis of using two criteria for decision making of aspirin use for the primary prevention of ischemic cardiovascular disease in outpatients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Apr 24;46(4):298-303. [PubMed: 29747326]
12.Migliara G, Baccolini V, Rosso A, D’Andrea E, Massimi A, Villari P, De Vito C. Familial Hypercholesterolemia: A Systematic Review of Guidelines on Genetic Testing and Patient Management. Front Public Health. 2017;5:252. [PMC free article: PMC5622145] [PubMed: 28993804]
13.Tomlinson B, Chan JC, Chan WB, Chen WW, Chow FC, Li SK, Kong AP, Ma RC, Siu DC, Tan KC, Wong LK, Yeung VT, But BW, Cheung PT, Fu CC, Tung JY, Wong WC, Yau HC. Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoin. Hong Kong Med J. 2018 Aug;24(4):408-415. [PubMed: 30100583]
14.McPherson R. The Cardiovascular Burden of Undiagnosed Familial Hypercholesterolemia: Need to Modify Guidelines to Encourage Earlier Diagnosis and Therapy. Can J Cardiol. 2018 Sep;34(9):1112-1113. [PubMed: 30093301]
15.Harada-Shiba M, Arai H, Ishigaki Y, Ishibashi S, Okamura T, Ogura M, Dobashi K, Nohara A, Bujo H, Miyauchi K, Yamashita S, Yokote K., Working Group by Japan Atherosclerosis Society for Making Guidance of Familial Hypercholesterolemia. Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017. J Atheroscler Thromb. 2018 Aug 01;25(8):751-770. [PMC free article: PMC6099072] [PubMed: 29877295]
16.Castelnuovo G, Pietrabissa G, Manzoni GM, Corti S, Ceccarini M, Borrello M, Giusti EM, Novelli M, Cattivelli R, Middleton NA, Simpson SG, Molinari E. Chronic care management of globesity: promoting healthier lifestyles in traditional and mHealth based settings. Front Psychol. 2015;6:1557. [PMC free article: PMC4606044] [PubMed: 26528215]
17.Fidelix YL, Farias Júnior JC, Lofrano-Prado MC, Guerra RL, Cardel M, Prado WL. Multidisciplinary intervention in obese adolescents: predictors of dropout. Einstein (Sao Paulo). 2015 Jul-Sep;13(3):388-94. [PMC free article: PMC4943784] [PubMed: 26466062]
18.Vickery AW, Bell D, Garton-Smith J, Kirke AB, Pang J, Watts GF. Optimising the detection and management of familial hypercholesterolaemia: central role of primary care and its integration with specialist services. Heart Lung Circ. 2014 Dec;23(12):1158-64. [PubMed: 25130889]
19.Gorina M, Limonero JT, Álvarez M. Effectiveness of primary healthcare educational interventions undertaken by nurses to improve chronic disease management in patients with diabetes mellitus, hypertension and hypercholesterolemia: A systematic review. Int J Nurs Stud. 2018 Oct;86:139-150. [PubMed: 30007585]
